Entera Bio says Phase 2 post-hoc analysis supports anabolic effect of oral EB613 in high-risk postmenopausal osteoporosis patients
Reuters2026/08/04 12:35- Entera Bio flagged new post-hoc Phase 2 analyses of EB613, an oral bone-forming osteoporosis tablet, selected for presentation at ASBMR 2026.
- Results were not previously disclosed; they are scheduled for October 9-12, 2026, including a plenary poster session.
- The analysis indicates stronger bone-building effects in postmenopausal women with more severe osteoporosis and higher fracture risk.
- Entera plans a single Phase 3 trial in about 750 postmenopausal women to support a potential NDA filing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Xenia Hôtellerie Solution announces extraordinary shareholder meeting
Community Reacts As Pundit Claims XRP Will Be Priced At $2,953 By Q2 2027
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
Crypto prices
More
